Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development

Bibliography

• Flynn NM, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trail of a recombinant glycoprotein120 vaccine to prevent HIV-1 infection. J Infect Dis 2005;191:654-65
   PubMed Web of Science ®Google Scholar
• Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006;43:500-11
   PubMed Web of Science ®Google Scholar
• Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-9
   PubMed Web of Science ®Google Scholar
• Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 2007;27:406-16
   PubMed Web of Science ®Google Scholar
• Gordon SN, Klatt NR, Bosinger SE, et al. Severe depletion of mucosal CD4+ T-cells in AIDS-free simian immunodeficiency virus-infected sooty mangabeys. J Immunol 2007;179:3026-34
   PubMed Web of Science ®Google Scholar
• Pandrea IV, Gautam R, Ribeiro RM, et al. Acute loss of intestinal CD4+ T-cells is not predictive of simian immunodeficiency virus virulence. J Immunol 2007;179:3035-46
   PubMed Web of Science ®Google Scholar
• Johnston MI, Fauci AS. An HIV vaccine-evolving concepts. N Engl J Med 2007;356:2073-81
   PubMed Web of Science ®Google Scholar
• Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4+ central memory T-cells and survival in vaccinated SIV-challenged monkeys. Science 2006;312:1530-3
   PubMed Web of Science ®Google Scholar
• Seth A, Ourmanov I, Schmitz JE, et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) gag-pol primes for an anamnestic gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 2000;74:2502-9
   PubMed Web of Science ®Google Scholar
• Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus macaques by cytokine-augmented DNA vaccination. Science 2000;290:486-92
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002;415:331-5
   PubMed Web of Science ®Google Scholar
• Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857-60
   PubMed Web of Science ®Google Scholar
• Baba RW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000;6:200-6
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, Vancott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000;6:207-10
   PubMed Web of Science ®Google Scholar
• Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 2001;73:4009-18
   Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001;75:9340-7
   Google Scholar
• Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4- binding site antibodies. Nat Med 2007;13:1032-4
   PubMed Web of Science ®Google Scholar
• Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4+ T-cells in multiple tissues during SIV infection. Nature 2005;434:1093-7
   PubMed Web of Science ®Google Scholar
• Veazy RS, Mansfield RG, Tham IC, et al. Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4+ T-cells are rapidly eliminated in early SIV infection. J Virol 2000;74:57-64
   PubMed Web of Science ®Google Scholar
• Li Q, Lifson JD, Duan L, et al. Peak SIV replication in resting memory CD4+ T-cells depletes gut lamina propria CD4+ T-cells. Nature 2005;434:1148-52
   PubMed Web of Science ®Google Scholar
• Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006;12:289-95
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol 2006;7:235-9
   PubMed Web of Science ®Google Scholar
• Daniel MD, Kirchhoff F, Czajak SC, et al. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992;258:1938-41
   PubMed Web of Science ®Google Scholar
• Wyand MS, Manson K, Montefiori DC, et al. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999;73:8356-63
   PubMed Web of Science ®Google Scholar
• Whatmore AM, Cook N, Hall GA, et al. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 1995;69:5117-23
   PubMed Web of Science ®Google Scholar
• Wyand MS, Manson KH, Lackner AA, Desrosiers RC. Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus. Nature 1997;3:32-6
   Web of Science ®Google Scholar
• Baba TW, Jeong YS, Pennick D, et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995;267:1820-5
   PubMed Web of Science ®Google Scholar
• Van Ginkel FW, Nguyen HH, Mcghee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis 2000;6:123-32
   PubMed Web of Science ®Google Scholar
• Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999;5:194-203
   PubMed Web of Science ®Google Scholar
• Whitney JB, Ruprecht RM. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004;17:17-26
   PubMed Web of Science ®Google Scholar
• Matano T, Kano M, Nakamura H, et al. Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai viral vector boost regimen. J Virol 2001;75:11891-6
   PubMed Web of Science ®Google Scholar
• Crotty S, Andino R. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv Drug Deliv Rev 2004;56:835-52
   PubMed Web of Science ®Google Scholar
• Wen J. Phase I study of China's compound HIV/AIDS vaccine begins. Available from: http://www.asia-lifesciences.com/news_index.php?itemID=25phasa1-hiv-aids-peking [Last Accessed 16 June 2008]
   Google Scholar
• Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007;6:255-66
   PubMed Web of Science ®Google Scholar
• Hilleman M. Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine 2002;20:651-65
   Web of Science ®Google Scholar
• Zuniga A, Wang Z, Liniger M, et al. Attenuated measles virus as a vaccine vector. Vaccine 2007;25:2974-83
   PubMed Web of Science ®Google Scholar
• Wang Z, Hangartner L, Cornu TI, et al. Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. Vaccine 2001;19:2329-36
   PubMed Web of Science ®Google Scholar
• Lorin C, Mollet L, Delebecque F, et al. A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV. J Virol 2004;78:146-57
   PubMed Web of Science ®Google Scholar
• Singh M, Cattaneo R, Billeter MA. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. J Virol 1999;73:4823-8
   PubMed Web of Science ®Google Scholar
• Despres P, Combredet C, Frenkiel MP, et al. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005;191:207-14
   PubMed Web of Science ®Google Scholar
• Dilraj A, Cutts FT, De Castro JF, et al. Response to different measles vaccine strains given by aerosol and subcutaneous routes to schoolchildren: a randomized trial. Lancet 2000;355:798-803
   PubMed Web of Science ®Google Scholar
• Bennett JV, Fernandez De Castro J, Valdespino-Gomez JL, et al. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren. Bull World Health Organ 2002;80:806-12
   PubMed Web of Science ®Google Scholar
• Cline BL. Ecological associations of vesicular stomatitis virus in rural Central America and Panama. Am J Trop Med Hyg 1976;25:875-83
   PubMed Web of Science ®Google Scholar
• Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 1995;92:4477-81
   PubMed Web of Science ®Google Scholar
• Roberts A, Buonocore L, Price R, et al. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 1999;73:3723-32
   PubMed Web of Science ®Google Scholar
• Roberts A, Kretzschmar E, Perkins AS, et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 1998;72:4704-11
   PubMed Web of Science ®Google Scholar
• Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49
   PubMed Web of Science ®Google Scholar
• Publicover J, Ramsburg E, Rose JK. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J Virol 2005;79:13231-8
   PubMed Web of Science ®Google Scholar
• Egan MA, Chong SY, Rose NF, et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004;20:989-1004
   PubMed Web of Science ®Google Scholar
• Reiss CS, Plakhov IV, Komatsu T. Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann NY Acad Sci 1998;855:751-61
   PubMed Web of Science ®Google Scholar
• Johnson JE, Nasar F, Coleman JW, et al. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 2007;360:36-49
   PubMed Web of Science ®Google Scholar
• Chen ST, Iida A, Guo L, et al. Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system. Proc Natl Acad Sci USA 1996;93:10057-62
   PubMed Web of Science ®Google Scholar
• Egan MA, Chong SY, Megati S, et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005;21:629-43
   PubMed Web of Science ®Google Scholar
• Gilbert PB, Chiu Y-L, Allen M, et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored phase I and II clinical trials. Vaccine 2003;21:2933-47
   PubMed Web of Science ®Google Scholar
• Cooney EL, Collier AC, Greenberg PD, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567-72
   PubMed Web of Science ®Google Scholar
• Shen L, Chen ZW, Miller MD, et al. Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes. Science 1991;252:440-3
   PubMed Web of Science ®Google Scholar
• Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992;166:244-52
   PubMed Web of Science ®Google Scholar
• Redfield RR, Wright DC, James WD, et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 1987;316:673-6
   PubMed Web of Science ®Google Scholar
• Malkevitch NV, Robert-Guroff M. A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines 2004;4(3)(Suppl):105-17
   Google Scholar
• Robert-Guroff M. Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotech 2007;18:1-11
   Web of Science ®Google Scholar
• Banchereau, J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52
   PubMed Web of Science ®Google Scholar
• Van Der Veen J, Lambriex M. Relationship of adenovirus to lymphocytes in naturally infected human tonsils and adenoids. Virology 1973;7:604-9
   Google Scholar
• Matsuse T, Hayashi S, Kuwano K, et al. Latent adenoviral infection in the pathogenesis of chronic airways obstruction. Am Rev Respir Dis 1992;146:177-84
   PubMed Web of Science ®Google Scholar
• Gaydos CA, Gaydos JC. Adenovirus vaccines in the U.S. military. Mil Med 1995;160:300-4
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Nabel GL, Shiver JW. Replication-defective and competent adenovirus recombinants as vaccine vectors. In: Levine MM, editor, New generation vaccines. 4th edition. Informa Healthcare; 2008. In press
   Google Scholar
• Chanock RM, Ludwig W, Heubner RJ, et al. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue cultures. I. Safety and lack of oncogenicity and tests for potency in volunteers. JAMA 1966;195:445-52
   PubMed Web of Science ®Google Scholar
• Edmondson WP, Purcell RH, Gundelfinger BF, et al. Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. Specific protective effect against epidemic disease. JAMA 1966;195:453-9
   PubMed Web of Science ®Google Scholar
• Rosenbaum MJ, De Berry P, Sullivan EJ, et al. Characteristics of vaccine-induced and natural infection with adenovirus type 4 in naval recruits. Am J Epidemiol 1968;88:45-54
   PubMed Web of Science ®Google Scholar
• Mueller RE, Muldoon RL, Jackson GG. Communicability of enteric live adenovirus type 4 vaccine in families. J Infect Dis 1969;119:60-6
   PubMed Web of Science ®Google Scholar
• Lichtenstein DL, Wold WSM. Experimental infection of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety and transmission. Cancer Gene Ther 2004;11:819-29
   PubMed Web of Science ®Google Scholar
• Tacket CO, Losonsky G, Lubeck MD, et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 1992;10:673-6
   PubMed Web of Science ®Google Scholar
• Lubeck MD, Davis AR, Chengalvala M, et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci USA 1989;86:6763-7
   PubMed Web of Science ®Google Scholar
• Bhat BM, Bhat RA, Chengalvala MV, et al. Comparative analysis of high expression adeno-HBsAg recombinants with and without E3 region proteins in tissue culture, dogs, and chimpanzees. In: Norrby E, Brown F, Chanock RM, Ginsberg HS, editors, Vaccines 94. Cold Spring Harbor Laboratory Press: Cold Spring Harbor; 1994. p. 309-14
   Google Scholar
• Chengalvala MV, Bhat BM, Bhat RA, et al. Replication and immunogenicity of Ad7-, Ad4-, and Ad5-hepatitis B virus surface antigen recombinants, with or without a portion of E3 region, in chimpanzees. Vaccine 1997;15:335-9
   PubMed Web of Science ®Google Scholar
• Prevec L, Christie BS, Laurie KE, et al. Immune response to HIV-1 Gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J Acquir Immun Defic Syndr 1991;4:568-76
   PubMed Web of Science ®Google Scholar
• Natuk RJ, Chanda PK Lubeck MD, et al. Adenovirus-human immunodeficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc Natl Acad Sci USA 1992;89:7777-81
   PubMed Web of Science ®Google Scholar
• Lubeck MD Natuk RJ Chengalvala M, et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 1994;10:1443-9
   PubMed Web of Science ®Google Scholar
• Lubeck MD, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 1997;3:651-8
   PubMed Web of Science ®Google Scholar
• Zolla-Pazner S, Lubeck M, Xu S, et al. Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol 1998;72:1052-9
   PubMed Web of Science ®Google Scholar
• Robert-Guroff M, Kaur H, Patterson LJ, et al. Vaccine protection against a heterologous, non-syncytium-inducing primary human immunodeficiency virus. J Virol 1998;72:10275-80
   PubMed Web of Science ®Google Scholar
• Cheng SM, Lee SG, Ronchetti-Blume M, et al. Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J Virol 1992;66:6721-7
   PubMed Web of Science ®Google Scholar
• Buge SL, Richardson E, Alipanah S, et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997;71:8531-41
   PubMed Web of Science ®Google Scholar
• Buge SL, Murty L, Arora K, et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 1999;73:7430-40
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74
   PubMed Web of Science ®Google Scholar
• Petry H, Pekrun K, Hunsmann G, et al. Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine. J Virol 2000;74:11145-52
   PubMed Web of Science ®Google Scholar
• Schwartz S, Campbell M, Nasioulas G, et al. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 1992;66:7176-82
   PubMed Web of Science ®Google Scholar
• Schneider R, Campbell M, Nasioulas G, et al. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997;71:4892-903
   PubMed Web of Science ®Google Scholar
• Zhao J, Lou Y, Pinczewski J, et al. Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIV env/rev and Ad5hr-SIV gag recombinants. Vaccine 2003;21:4022-35
   PubMed Web of Science ®Google Scholar
• Zhao J, Pinczewski J, Gomez-Roman VR, et al. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIVmac251 challenge by a replication-competent Ad5hr-SIV env/rev and Ad5hr-SIV gag recombinant priming/gp120 boosting regimen. J Virol 2003;77:8354-65
   PubMed Web of Science ®Google Scholar
• Patterson LJ, Malkevitch N, Zhao J, et al. Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol 2002;21:627-35
   PubMed Web of Science ®Google Scholar
• Robey FA, Kelson-Harris T, Roller PP, Robert-Guroff M. A helical epitope in the C4 domain of HIV glycoprotein 120. J Biol Chem 1995;270:23918-21
   PubMed Web of Science ®Google Scholar
• Robey FA, Harris-Kelson T, Robert-Guroff M, et al. A synthetic conformational epitope from the C4 domain of HIV gp120 that binds CD4. J Biol Chem 1996;271:17990-5
   PubMed Web of Science ®Google Scholar
• Patterson LL, Malkevitch N, Pinczewski J, et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIVgp120. J Virol 2003;77:8607-20
   PubMed Web of Science ®Google Scholar
• Malkevitch N, Patterson LJ, Aldrich K, et al. A replication competent adenovirus 5 host range mutant-simian immunodeficiency virus (SIV) recombinant priming/subunity protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in Mamu-A*01 rhesus macaques. J Immunol 2003;170:4281-9
   PubMed Web of Science ®Google Scholar
• Patterson LJ, Malkevitch N, Venzon D, et al. Protection against mucosal simian immunodeficiency virus SIVmac251 challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 2004;78:2212-21
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005;174:2185-9
   PubMed Web of Science ®Google Scholar
• Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449:101-4
   PubMed Web of Science ®Google Scholar
• Malkevitch NV, Patterson LJ, Aldrich MK, et al. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 2006;353:83-98
   PubMed Web of Science ®Google Scholar
• Zhou Q, Hidajat R, Peng B, et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIVmac251. Vaccine 2007; 25:8021-35
   PubMed Web of Science ®Google Scholar
• Cafaro A, Caputo A, Fracasso C, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999;5:643-50
   PubMed Web of Science ®Google Scholar
• Cafaro A, Titti F, Fracasso C, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian-human immunodeficiency virus (SHIV 89.6P). Vaccine 2001;19:2862-77
   PubMed Web of Science ®Google Scholar
• Demberg T, Florese RH, Heath MJ, et al. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env. priming/tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2007;81:3414-27
   PubMed Web of Science ®Google Scholar
• Zhao J, Voltan R, Peng B, et al. Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology 2005;342:1-12
   PubMed Web of Science ®Google Scholar
• Fanales-Belasio E, Moretti S, Nappi F, et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002;168:197-206
   PubMed Web of Science ®Google Scholar
• Moy P, Daikh Y, Pepinsky B, et al. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol Biotechnol 1996;6:105-13
   PubMed Web of Science ®Google Scholar
• Cristillo AD, Wang S, Caskey MS, et al. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine. Virology 2006;346:151-68
   PubMed Web of Science ®Google Scholar
• Shu Y, Winfrey S, Yang Z-Y, et al. Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs. Vaccine 2006;25:1398-408
   PubMed Web of Science ®Google Scholar
• Patterson LJ, Beal J, Demberg T, et al. Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques. Virology 2008;374(2):322-37
   PubMed Web of Science ®Google Scholar
• Bogers WMJM, Davis D, Baak I, et al. HIV-1 vaccine protection from mucosal SHIV infection correlates with systemic neutralizing antibody titers [abstract #42]. Presented at the 25th Annual symposium on Nonhuman Primate Models for AIDS; 10 – 13 September 2007; Monterey, CA
   Google Scholar
• Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120. Negative results fail to trigger a phase 2 correlates trial. J Acquir Imm Defic Syndr 2007;44:203-12
   PubMed Web of Science ®Google Scholar
• IAVI Report: IAVI database of AIDS vaccines in human trials. Updated 27 September 2007. Available from: http://www.iavireport.org/trialsdb [Last accessed 16 June 2008]
   Google Scholar
• Kent S, De Rose R, Rollman E. Drug evaluation: DNA/MVA prime-boost HIV vaccine. Curr Opin Invest Drugs 2007;8:159-67
   PubMed Web of Science ®Google Scholar
• Santra S, Sun Y, Parvani JG, et al. Heterologous prime/boost immunization of rhesus macaques by using diverse poxvirus vectors. J Virol 2007;81:8563-70
   PubMed Web of Science ®Google Scholar
• Harari A, Bart P-A, Stohr W, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccinia regimen induces reliable, polyfunctional, and long-lasting T-cell responses. J Exp Med 2008;205:63-77
   PubMed Web of Science ®Google Scholar
• Tritel M, Stoddard AM, Flynn BJ, et al. Prime-boost vaccination with HIV-1 Gag protein and cytosine phosphate guanosine oligodeoxynucleotide, followed by adenovirus, induces sustained and robust humoral and cellular immune responses. J Immunol 2003;171:2538-47
   PubMed Web of Science ®Google Scholar
• Peng B, Wang LR, Gomez-Roman VR, et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J Virol 2005;79:10200-9
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Florese RH, Peng B, et al. An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Imm Defic Syndr 2006;43:270-7
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AAC, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007;81:4654-63
   PubMed Web of Science ®Google Scholar
• McCoy K, Tatsis N, Korioth-Schmitz B, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 2007;81:6594-604
   PubMed Web of Science ®Google Scholar
• Kostense S, Koudstaal W, Sprangers M, et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004;18:1213-6
   PubMed Web of Science ®Google Scholar
• Liang X, Casimiro DR, Schleif WA, et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005;79:12321-31
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Wang F, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005;79:15547-55
   PubMed Web of Science ®Google Scholar
• Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006;194:1638-49
   PubMed Web of Science ®Google Scholar
• Graham BS, Koup RA, Roederer, M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006;194:1650-60
   PubMed Web of Science ®Google Scholar
• Cohen J. Promising AIDS vaccine's failures leaves field reeling. Science 2007;318:28-9
   PubMed Web of Science ®Google Scholar
• Available from: http://www.hvtn.org/science/1107.html
   Google Scholar
• Robertson M, Mehrotra D, Fitzgerald D, et al. Efficacy results from the STEP study (Merck V520 Protocol 023/HVTN 502): a phase II test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine [abstract #88LB]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections; 3 – 6 February 2008; Boston, MA
   Google Scholar
• Natuk RJ, Lubeck MD, Chanda PK, et al. Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 1993;9:395-404
   PubMed Web of Science ®Google Scholar
• Smith TJ, Buescher EL, Top FH Jr, et al. Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses. J Infect Dis 1970;122:239-48
   PubMed Web of Science ®Google Scholar
• Gutekunst RR, White RJ, Edmondson WP, Chanock RM. Immunization with live type 4 adenovirus: determination of infectious virus dose and protective effect of enteric infection. Am J Epidemiol 1967;86:341-9
   PubMed Web of Science ®Google Scholar
• Stanley ED, Jackson GG. Spread of enteric live adenovirus type 4 vaccine in married couples. J Infect Dis 1969;119:51-9
   PubMed Web of Science ®Google Scholar
• Gomez-Roman VR, Grimes GJ Jr, Potti GK, et al. Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV and SHIV-infected rhesus macaques. Vaccine 2006;24:5064-72
   PubMed Web of Science ®Google Scholar
• Kresge KJ. A STEP back? Additional data released from the STEP trial raises questions about whether the vaccine may have increased the risk of HIV infection. IAVI Report 2007; 11: September–December. Available from: http://www.iavireport.org/Issues/Issue11-5/Step.asp [Last accessed 19 June 2008]
   Google Scholar
• Robertson R, Casimiro D, De Rosa S, et al. Immunological characterization of subjects from the STEP study: a phase IIB test-of-concept trial of the MRKAd5 HIV-1 Gag/Pol/Nef trivalent vaccine [abstract #89LB]. Presented at the 15th Conference on Retroviruses and Opportunistic Infections; 3 – 6 February 2008; Boston, MA
   Google Scholar
• Ludwig SL, Brundage JF, Kelley PW, et al. Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis 1998;178:1776-8
   PubMed Web of Science ®Google Scholar
• Beck Z, Prohaszka Z, Fust G. Traitors of the immune system – enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development. Vaccine 2008;26:3078-85
   PubMed Web of Science ®Google Scholar
• Pandrea I, Apetrei C, Dufour J, et al. Simian immunodeficiency virus SIVagm.sab infection of Caribbean African green monkeys: a new model for the study of SIV pathogenesis in natural hosts. J Virol 2006;80:4858-67
   PubMed Web of Science ®Google Scholar